The TANGO trial (Targeting Tau with Antibodies for Neurodegeneration and Global Outcomes) represented a landmark Phase 2 clinical trial evaluating semorinemab (also known as RG6100), an anti-tau monoclonal antibody developed by Genentech (a member of the Roche group), in patients with prodromal to moderate Alzheimer's disease. This trial was one of the largest and most comprehensive evaluations of tau-targeted immunotherapy in Alzheimer's disease conducted to date, enrolling 432 patients across 90 sites in 15 countries over a 52-week treatment period[@semorinemab2022].
The scientific rationale underlying the TANGO trial reflected a paradigm shift in Alzheimer's disease therapeutic development. While the field had focused primarily on amyloid-beta targeting for decades, accumulating evidence suggested that tau pathology—particularly the spread of neurofibrillary tangles composed of hyperphosphorylated tau protein—correlated more closely with cognitive decline than amyloid burden alone. By targeting tau pathology directly, semorinemab aimed to address what many researchers considered the "downstream" pathological process that ultimately mediates neuronal dysfunction and cognitive impairment in Alzheimer's disease[@tau2023].
The TANGO trial (Targeting Tau with Antibodies for Neurodegeneration and Global Outcomes) represented a landmark Phase 2 clinical trial evaluating semorinemab (also known as RG6100), an anti-tau monoclonal antibody developed by Genentech (a member of the Roche group), in patients with prodromal to moderate Alzheimer's disease. This trial was one of the largest and most comprehensive evaluations of tau-targeted immunotherapy in Alzheimer's disease conducted to date, enrolling 432 patients across 90 sites in 15 countries over a 52-week treatment period[@semorinemab2022].
The scientific rationale underlying the TANGO trial reflected a paradigm shift in Alzheimer's disease therapeutic development. While the field had focused primarily on amyloid-beta targeting for decades, accumulating evidence suggested that tau pathology—particularly the spread of neurofibrillary tangles composed of hyperphosphorylated tau protein—correlated more closely with cognitive decline than amyloid burden alone. By targeting tau pathology directly, semorinemab aimed to address what many researchers considered the "downstream" pathological process that ultimately mediates neuronal dysfunction and cognitive impairment in Alzheimer's disease[@tau2023].
Despite not meeting its primary endpoint of demonstrating clinical benefit on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at week 52, the TANGO trial provided crucial insights into tau immunotherapy that continue to inform clinical trial design and development of next-generation therapeutics. The trial demonstrated clear target engagement through significant reduction in cerebrospinal fluid (CSF) phosphorylated tau (p-tau181), establishing that antibody-mediated targeting of tau pathology is biologically achievable in humans[@mall2023].
The tau protein is a microtubule-associated protein expressed primarily in neurons, where it plays essential roles in maintaining microtubule stability, regulating axonal transport, and supporting neuronal morphology. In Alzheimer's disease, tau undergoes pathological transformations that contribute to neurodegeneration through multiple mechanisms[@bloom2023]:
Hyperphosphorylation: Under pathological conditions, tau becomes abnormally phosphorylated at numerous sites, reducing its affinity for microtubules and impairing its normal physiological functions. This hyperphosphorylated tau accumulates within neurons, eventually forming paired helical filaments (PHFs) and straight filaments that aggregate into neurofibrillary tangles (NFTs).
Aggregation: Hyperphosphorylated tau monomers assemble into oligomers, then into larger aggregates, and finally into the insoluble neurofibrillary tangles observed in Alzheimer's disease brain tissue. This aggregation process is believed to be toxic to neurons through multiple mechanisms including synaptic dysfunction, mitochondrial impairment, and neuroinflammation.
Propagation: Perhaps most significant for therapeutic development, tau pathology exhibits a characteristic pattern of spread through connected brain networks. Pathological tau appears to propagate between neurons in a prion-like manner, moving along neural circuits and spreading from affected to connected brain regions. This propagation mechanism provides a rationale for intervention: blocking the spread of pathological tau could potentially slow or halt disease progression.
Active and passive immunotherapy targeting tau represents one of the most promising therapeutic approaches for Alzheimer's disease. Unlike amyloid-directed therapies that aim to prevent initial plaque formation, tau-targeted approaches seek to address the pathological process that more directly correlates with clinical symptoms[@sigurdsson2022].
The rationale for passive immunization with anti-tau monoclonal antibodies includes:
Semorinemab (RG6100) is a humanized IgG4 monoclonal antibody engineered to target specific epitopes within the tau protein. Its mechanism of action combines multiple therapeutic approaches[@fotianos2022]:
Epitope Specificity: Semorinemab binds to an epitope in the mid-domain of tau (amino acids 184-360), a region distinct from both N-terminal and C-terminal regions targeted by other tau antibodies. This mid-domain binding is thought to enable recognition of both monomeric and aggregated tau species while avoiding binding to normal physiological tau.
Aggregate Recognition: The antibody demonstrates high affinity for pathological tau conformations, including soluble oligomers and insoluble aggregates, enabling targeting of the most toxic tau species.
Peripheral Sink Effect: By binding tau in the periphery (including within the CSF compartment), semorinemab may create a gradient that promotes clearance of central nervous system tau through enhanced drainage and degradation.
Fc-Mediated Effector Functions: The IgG4 isotype was selected to minimize Fc receptor-mediated inflammatory responses while maintaining ability to engage cellular clearance mechanisms through other pathways.
The TANGO trial was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability, and efficacy of semorinemab in subjects with prodromal to moderate Alzheimer's disease[@semorinemab2022].
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT03289143 |
| Phase | Phase 2 |
| Status | Completed |
| Sponsor | Genentech (Roche) |
| Enrollment | 432 patients |
| Duration | 52 weeks |
| Study Period | 2017-2021 |
| Countries | US, Canada, Europe, Australia, Japan |
| Sites | Approximately 90 |
Disease Stage: The trial enrolled participants across a broad disease spectrum from prodromal Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease) to moderate Alzheimer's disease dementia.
Biomarker Confirmation: All participants required biomarker evidence of both amyloid and tau pathology:
Key Inclusion Criteria:
Participants were randomized in a 1:1:1:1 ratio to one of four treatment groups:
| Arm | Dose | Dosing Frequency | Route |
|-----|------|------------------|-------|
| 1 | Placebo | Every 4 weeks | IV infusion |
| 2 | 1,500 mg | Every 4 weeks | IV infusion |
| 3 | 4,500 mg | Every 4 weeks | IV infusion |
| 4 | 6,100 mg | Every 4 weeks | IV infusion |
Randomization was stratified by:
Primary Endpoint:
The TANGO trial did not meet its primary efficacy endpoint. At week 52, there was no statistically significant difference between any semorinemab dose group and placebo in change from baseline in CDR-SB scores[@semorinemab2022].
CDR-SB Results:
| Treatment | Change from Baseline | vs. Placebo Difference |
|-----------|---------------------|------------------------|
| Placebo | +0.86 | -- |
| 1,500 mg | +0.87 | +0.01 |
| 4,500 mg | +0.72 | -0.14 |
| 6,100 mg | +0.81 | -0.05 |
The lack of clinical benefit was consistent across all dose groups, suggesting that either the therapeutic mechanism was insufficient to modify disease progression, or that the 52-week treatment duration was inadequate to detect clinical effects.
Despite the lack of clinical benefit, the trial demonstrated clear target engagement through biomarker effects[@gauthier2022]:
CSF Biomarkers:
Exploratory post-hoc analyses revealed potentially important findings that warrant further investigation[@gauthier2022]:
Disease Stage Effects:
Semorinemab demonstrated an acceptable safety profile across all dose groups:
Adverse Events:
Despite not demonstrating clinical benefit, the TANGO trial provided invaluable insights that continue to shape tau-directed therapeutic development[@mall2023]:
The TANGO results have influenced design of subsequent trials:
Endpoint Selection: Recognition that traditional cognitive measures may be insensitive to tau-directed effects has prompted exploration of more sensitive cognitive composites and biomarker-driven endpoints.
Patient Selection: Emphasis on enrolling patients at earlier disease stages, where pathological burden is lower and potential for benefit greater.
Biomarker-Driven Enrichment: More rigorous biomarker confirmation requirements to ensure participants have the relevant target pathology.
Based on TANGO learnings, several next-generation approaches are being pursued:
Earlier Intervention: Trials in preclinical Alzheimer's disease populations before significant tau pathology has developed.
Higher Doses: Exploration of higher dosing regimens to achieve more complete target engagement.
Combination Therapy: Concurrent targeting of amyloid and tau pathology.
Alternative Formats: Active vaccination approaches and bispecific antibodies.
Semorinemab exhibits typical monoclonal antibody pharmacokinetics characterized by slow elimination and limited CNS penetration:
| Parameter | Value |
|-----------|-------|
| Half-life | 21-28 days |
| Volume of distribution | 3.5-4.5 L |
| Clearance | 0.12-0.18 L/day |
| Cmax | Dose-proportional |
| AUC0-∞ | Dose-proportional |
CSF Penetration:
Based on CSF sampling in participants, semorinemab demonstrated measurable CNS penetration:
The relationship between exposure and biomarker response showed EC50: 150 μg·day/mL, with near-maximal effect at 4,500 mg dose. No clear clinical exposure-response was observed.
Biomarker Exposure-Response:
Post-hoc analyses showed greater biomarker reduction in early-stage participants, supporting earlier intervention approaches.
Early-Stage Benefits:
Favorable: Lower tau PET burden, short disease duration, younger age.
Less favorable: High tau PET burden, long disease duration, older age.
The field has moved toward biomarker-driven selection for tau immunotherapy trials:
Current Selection Criteria:
| Program | Company | Target | Stage |
|---------|--------|--------|-------|
| Semorinemab | Roche/Genentech | Mid-domain tau | Phase 2 |
| LMTM | Axon Neuroscience | Tau epitope | Phase 3 |
| BIIB092 | Biogen | N-terminal tau | Phase 2 |
| JNJ-63733681 | Janssen | Tau oligomers | Phase 1 |
| ABBV-8E12 | AbbVie | Abnormal tau | Phase 2 |
Roche has positioned semorinemab within a broader AD pipeline strategy:
Tau immunotherapy represents significant healthcare investment:
Cost Considerations:
Post-approval real-world evidence will be critical:
Registry Studies:
Based on TANGO learnings, enhanced approaches are in development:
Enhanced Mechanisms:
Engagement with regulatory authorities has informed development:
FDA Interactions: